Welcome to our dedicated page for Repare Therapeutics Common Shares news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics Common Shares stock.
Repare Therapeutics Inc. (RPTX) is a pioneering precision medicine oncology company dedicated to the advancement of synthetic lethality-based therapies for cancer patients. The company's mission is to develop innovative oncology drugs that specifically target the vulnerabilities of tumor cells in genetically defined patient populations.
Repare utilizes an integrated approach combining insights from multiple fields of cell biology, including DNA repair and synthetic lethality. Their proprietary platform employs a high-throughput, CRISPR-enabled gene editing target discovery method alongside high-resolution protein crystallography, computational biology, and clinical informatics.
Backed by prominent global healthcare investors such as Versant Ventures and MPM Capital, Repare Therapeutics is poised at the forefront of cancer treatment innovation. The company’s robust research and development pipeline is aimed at delivering groundbreaking treatments designed to improve patient outcomes.
Repare Therapeutics has made significant strides in the oncology field, participating in numerous clinical trials and forming strategic partnerships to expedite the delivery of effective cancer therapies. With a core focus on precision oncology, the company aims to address the unmet medical needs of cancer patients worldwide. The majority of its revenue is currently derived from its operations in Canada.
For more detailed information and the latest updates, you can visit their official website at www.reparerx.com.
Rhea-AI Summary
Repare Therapeutics Inc. announces participation in upcoming investor conferences to discuss precision oncology. Details include presentations at TD Cowen 44th Annual Healthcare Conference and Bloom Burton 2024 Healthcare Investor Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
-
Rhea-AI Summary
Repare Therapeutics Inc. reported financial results for Q4 and full year 2023, highlighting progress in their precision oncology programs. Key achievements include positive data from lunresertib trials, a partnership with Debiopharm, and a milestone payment from Roche. The company also disclosed plans for 2024, including new clinical trials and data readouts. Financially, Repare's cash position is strong, with $223.6 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary
Repare Therapeutics Inc. announces dosing of first patient in Phase 1 LIONS clinical trial for RP-1664, a potential first-in-class PLK4 inhibitor for solid tumors. RP-1664 shows promising tumor growth inhibition in TRIM37-high solid tumors and neuroblastoma models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
Rhea-AI Summary
Repare Therapeutics regains control of potential best-in-class oral small molecule ATR inhibitor, camonsertib, following termination of collaboration agreement with Roche. The company will now have full rights to develop and commercialize camonsertib, a promising precision oncology medicine that has shown clinical proof-of-concept in multiple tumor types and genotypes. Repare's deep clinical pipeline includes four wholly-owned synthetic lethal therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.58%
Tags
-
Rhea-AI Summary
Repare Therapeutics Inc. announced a $40 million milestone payment from Roche upon dosing of the first patient with camonsertib in Roche’s Phase 2 TAPISTRY trial. Repare is eligible to receive up to $1.2 billion in potential milestones, plus royalties on global net product sales. The collaboration also provides Repare with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
-
Rhea-AI Summary
Repare Therapeutics Inc. (RPTX) provides a corporate update and highlights key milestones anticipated in 2024. The company has advanced its pipeline significantly in 2023, presenting strong data from key programs such as lunresertib in combination with camonsertib, and camonsertib in combination with PARP inhibitors. Repare aims to expand its pipeline to four clinical-stage programs by the second half of 2024 and expects to share data readouts from ongoing studies of lunresertib combinations. The company also disclosed its partnership with Debiopharm to explore the potential clinical synergy of Debio 0123, a highly selective clinical WEE1 inhibitor, and lunresertib. Additionally, Repare announced key milestones anticipated in 2024, including the initiation of several Phase 1 studies and the reporting of data from ongoing studies. The company ended 2023 with approximately $223 million in cash, cash equivalents, and marketable securities, which is anticipated to fund planned operations into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.32%
Tags
Rhea-AI Summary
Repare Therapeutics Inc. (RPTX) collaborates with Debiopharm to investigate the combination of lunresertib, a PKMYT1 inhibitor, and Debio 0123, a WEE1 inhibitor, in a new arm of Repare’s ongoing global MYTHIC study. The Phase 1/1b clinical trial is anticipated to initiate in the first half of 2024. The collaboration aims to explore the synergy between the two compounds and share all costs equally. The combination has shown highly synergistic and promising preclinical data, demonstrating potential transformative benefit to patients with high unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
-
Rhea-AI Summary
Repare Therapeutics Inc. (Nasdaq: RPTX) announces the establishment of new Automatic Securities Disposition Plans (ASDPs) by its executive officers in accordance with U.S. and Canadian securities legislation. The ASDPs permit the orderly disposition of up to 929,670 common shares of Repare over approximately 15 months at prevailing market prices, with clear trading parameters and restrictions to prevent the use of material non-public information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
-
Rhea-AI Summary
Repare Therapeutics Inc. (Nasdaq: RPTX) announces the development of RP-1664, a potent PLK4 inhibitor, and RP-3467, a Polθ inhibitor, with promising preclinical data. RP-1664 shows synthetic lethality in TRIM37-high tumors, while RP-3467 demonstrates complete regressions in combination with PARPi and anti-tumor activity with RLT and chemotherapy. Clinical trials for RP-1664 and RP-3467 are expected to start in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.66%
Tags
Rhea-AI Summary
Repare Therapeutics Inc. (RPTX) reported positive initial data from the ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors. They also announced a conference call and webcast to discuss the latest data from their preclinical programs and overall pipeline on November 15th, 2023 at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.83%
Tags
FAQ
What is the current stock price of Repare Therapeutics Common Shares (RPTX)?
The current stock price of Repare Therapeutics Common Shares (RPTX) is $1.32 as of December 20, 2024.
What is the market cap of Repare Therapeutics Common Shares (RPTX)?
The market cap of Repare Therapeutics Common Shares (RPTX) is approximately 56.1M.
What does Repare Therapeutics Inc. specialize in?
Repare Therapeutics Inc. specializes in developing precision oncology drugs that target specific vulnerabilities in tumor cells using synthetic lethality-based therapies.
What unique technology does Repare Therapeutics use?
Repare Therapeutics employs a proprietary CRISPR-enabled gene editing target discovery method combined with high-resolution protein crystallography, computational biology, and clinical informatics.
Who are the major investors backing Repare Therapeutics?
Repare Therapeutics is supported by leading global healthcare investors, including Versant Ventures and MPM Capital.
Where does Repare Therapeutics derive its maximum revenue from?
The company derives the majority of its revenue from Canada.
What is the focus area of Repare Therapeutics' research and development?
Repare Therapeutics focuses its R&D on precision oncology, particularly targeting synthetic lethality-based therapies for cancer patients.
Where can I find more information about Repare Therapeutics?
More information can be found on their official website at www.reparerx.com.
How does Repare Therapeutics identify drug targets?
Repare identifies drug targets using their proprietary, high-throughput CRISPR-enabled gene editing platform.
What fields of cell biology does Repare Therapeutics integrate insights from?
Repare integrates insights from DNA repair and synthetic lethality in their research and development efforts.
What is the significance of synthetic lethality in Repare Therapeutics' approach?
Synthetic lethality allows Repare Therapeutics to develop drugs that target specific genetic vulnerabilities in tumor cells, making treatments more effective for genetically defined patient populations.
Is Repare Therapeutics involved in clinical trials?
Yes, Repare Therapeutics is actively participating in numerous clinical trials to expedite the delivery of effective cancer therapies.
Repare Therapeutics Inc. Common Shares
Nasdaq:RPTX
RPTX Rankings
RPTX Stock Data
56.11M
38.71M
0.95%
83.73%
1.43%
Biotechnology
Pharmaceutical Preparations
United States of America
SAINT-LAURENT